8:00 am Online Networking

8:45 am Chair’s Opening Remarks

• Simon Boulton Senior Group Leader, Francis Crick Institute Co-founder & VP Science Strategy Artios Pharma,

Assessing the Potential of PARP Inhibitors in Combination Therapies to Overcome Resistance Mechanisms

9:00 am The Potential of PARP & ATR Inhibitor Combinations

• Nicola Curtin Professor of Experimental Cancer Therapeutics, Newcastle University

9:00 am Targeting DNA Replication Stress Response in Cancer

• Sotirios K. Sotiriou Head of Biology & Co-Founder, FoRx Therapeutics

9:30 am Olaparib in Combination with Other Drugs: Novel Strategies to Overcome Resistance

• Elisabetta Leo Principal Scientist, AstraZeneca

9:30 am Inhibition of ATR: Progress from the Lab to the Clinic

• John Pollard Global Head Early Clinical Development & Translational Medicine Oncology, Bayer

Analyzing the Opportunities to Increase Therapeutic Index

10:00 am Targeting RNA Polymerase I Transcription Activates the DNA Damage Response & Demonstrates Therapeutic Efficacy in Ovarian Cancer

• Elaine Sanij Senior Research Fellow, Peter MacCallum Cancer Centre

10:30 am Virtual Speed Networking

11:30 am REV1 Inhibitor JH-RE-06 Enhances Tumor Cell Response to Chemotherapy by Triggering Senescence

• Nimrat Chatterjee Assistant Professor, Univeristy of Vermont

Identifying the Biomarkers of Response

12:00 pm Biomarker-Guided Development of DDR Drugs

• Alan D’Andrea Professor, Radiation Oncology , Harvard Medical School

12:30 pm Understanding Biomarkers & How They Can Predict Response

• Petar Jelinic Director, Translational Oncology & Clinical Biomarkers, Merck

1:00 pm Online Networking Lunch

2:00 pm Novel Genomic & Proteomic Approaches to DDRi Biomarker Identification

• Eric Brown Associate Professor of Cancer Biology, University of Pennsylvania

Patient Selection Strategies

2:30 pm Liquid Biopsy Pre & Post Rucaparib: Patient Selection & Mechanisms of Resistance in BRCA+ mCRPC

• Andrea Loehr Senior Director - Translational Medicine, Clovis Oncology

3:00 pm Single Agent SSR Activity – Identifying the Right Patients

• Ruth Plummer Professor of Experimental Cancer Medicine, Newcastle University

3:30 pm Chair’s Closing Remarks & End of Conference Day One

• Simon Boulton Senior Group Leader, Francis Crick Institute Co-founder & VP Science Strategy Artios Pharma,